Lv12
40 积分 2022-10-20 加入
Treatment Monitoring Program for Implementation of Adherence to Second-Line Erlotinib for Advanced Non–Small-Cell Lung Cancer
1小时前
待确认
Impact of a specialist clinical cancer pharmacist at a multidisciplinary lung cancer clinic
1小时前
已完结
Feasibility and Effectiveness of Self-Management Education and Coaching on Patient Activation for Managing Cancer Treatment Toxicities
2小时前
已完结
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
20小时前
已完结
Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib
6个月前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
6个月前
已完结
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
6个月前
已完结
Application of postoperative adjuvant radiotherapy in limited-stage small cell lung cancer: A systematic review and meta-analysis
6个月前
已完结
Adherence to Oral Anticancer Medications After Implementation of an Ambulatory Adherence Program at a Large Urban Academic Hospital
6个月前
已完结
Early Check-In Protocol: Identifying Medication Issues in Patients with Cancer at Health System Specialty Pharmacy
6个月前
已关闭
皖公网安备34019202002308
